More than 12 million patients are prescribed so-called "blood thinners" each year to prevent the formation of clots, which can block blood vessels, causing heart attacks, strokes and other debilitating or life-threatening conditions. Blood thinners, or antithrombotics, pose a risk of bleeding, particularly during surgery. The ability to stop the anti-clotting effects quickly could help protect patients from uncontrolled bleeding.
The Gill Heart Institute is one of two sites participating in the Phase 1 trial and is the first site to use the anti-clotting drug and its antidote.
This clinical trial will examine the drug's safety and tolerability in healthy volunteers as well as the antidote's ability to quickly reverse its effects. Although other new antithrombotics are undergoing testing in the U.S., this drug is believed to be the first of its kind.
"This class of drugs is a very promising technology that allows for the development of 'designer' drugs and their antidotes simultaneously," said Dr. Steven R. Steinhubl, the study's principal investigator at UK and director of cardiovascular education and clinical research at the Gill Heart Institute and a UK College of Medicine associate professor of cardiology. "It could have far-reaching implications."
"The research capacity of the cardiology division at UK has skyrocketed in the last year. Millions of dollars in research projects are under way, and we have attracted world-recognized leaders in drug discovery and development, such as Dr. Steinhubl. Leaders of technology and pharmaceutical companies have visited us in Lexington and are entrusting us to pioneer the next-generation of medicines and devices to improve healthcare," said Dr. David Moliterno, professor and vice chair of medicine, and chief, division of cardiovascular medicine, UK College of Medicine, and co-director of the UK Gill Heart Institute.
"Our goal is simple: we want to help patients with heart and vascular disorders by being at the forefront. Our research efforts are clearly bringing Kentuckians closer to the leading edge of the best medicine has to offer," Moliterno said.
The UK Linda and Jack Gill Heart Institute provides a central focus for cardiovascular disease care, including clinics; non-invasive cardiac diagnostics; invasive cardiac techniques such as cardiac catheterization, angioplasty and electrophysiology; a base for the physicians providing this care and a special focus on counseling cardiac patients and their families. The clinical programs of the institute target the high rate of heart disease prevalent in Kentucky, while the research and teaching programs work to advance cardiovascular care throughout the world.
The institute has its origins in the 1997 donation of $5 million from Linda and Jack Gill of Houston, Texas, to UK to build the Gill Heart Institute facility and establish three endowed chairs and 10 endowed professorships. Matching funds from the Kentucky Research Challenge Trust Fund augmented the Gills' donation.
In striving to become a Top-20 public research institution, the University of Kentucky is a catalyst for a new Commonwealth - a Kentucky that is healthier, better educated, and positioned to compete in a global and changing economy. For more information about UK's efforts to become a Top-20 university, please go to http://www.